Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTM2 | P28161 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664450 | 0.93 | GPR35 (0.50) | GSTM2MAPTTDP1MEN1KMT2A | |
| SCHEMBL3669432 | 0.86 | RAB9A (0.57) | MAPTTDP1MEN1KMT2AGPR35 | |
| SCHEMBL1894247 | 0.84 | GPR35 (0.49) | GSTM2MAPTTDP1MEN1KMT2A | |
| SCHEMBL11507064 | 0.83 | MAPT (0.57) | GSTM2MAPTTDP1MEN1KMT2A | |
| SCHEMBL31440090 | 0.83 | GPR35 (0.43) | GSTM2MAPTTDP1MEN1KMT2A | |
| SCHEMBL3668042 | 0.82 | SMN1; SMN2 (0.45) | GSTM2MAPTTDP1MEN1KMT2A | |
| SCHEMBL6469206 | 0.82 | MAPT (0.62) | MAPTTDP1MEN1KMT2AGPR35 | |
| SCHEMBL7745271 | 0.81 | KAT2B (0.69) | GSTM2MAPTMEN1KMT2ARAB9A | |
| SCHEMBL11445418 | 0.80 | MAPT (0.69) | MAPTTDP1KMT2AGPR35ALDH1A1 | |
| SCHEMBL3764898 | 0.78 | ALDH1A1 (0.51) | MAPTTDP1MEN1KMT2AGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901141-B2 | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| EP-2240485-B1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8785460-B2 | Tricyclic compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20100298287-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-2240485-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Takeda Pharmaceutical Company Limited (JP) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009093747-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, HCRTR1 | GSTM2 3429/4885MAPT 4205/4885TDP1 3481/4885 |
| US-20100298287-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CRH, CRHR1, CRHR2 | GSTM2 3895/4885MAPT 4194/4885TDP1 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.